Victor L. L. Villemagne

Victor L. L. Villemagne's AcademicInfluence.com Rankings

Philosophy

#6036

World Rank

#8998

Historical Rank

Logic

#3230

World Rank

#4356

Historical Rank

philosophy Degrees

Victor L. L. Villemagne

Biology

#8179

World Rank

#11216

Historical Rank

Neuroscience

#1116

World Rank

#1158

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Victor L. L. Villemagne's Degrees

PhD Neuroscience University of Melbourne
Doctorate Medicine University of Melbourne

Why Is Victor L. L. Villemagne Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Victor L. L. Villemagne's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study (2013) (1546)
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. (2015) (1112)
High performance plasma amyloid-β biomarkers for Alzheimer’s disease (2018) (969)
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging (2010) (950)
Activation of memory circuits during cue-elicited cocaine craving. (1996) (921)
β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease (2007) (719)
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease (2011) (718)
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease (2009) (680)
Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism (2008) (634)
Imaging β-amyloid burden in aging and dementia (2007) (610)
Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. (2015) (476)
Tau imaging: early progress and future directions (2015) (435)
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. (2007) (409)
Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography (2008) (401)
Relationship between atrophy and β‐amyloid deposition in Alzheimer disease (2010) (354)
Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease (2013) (318)
Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging. (2011) (304)
Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment (2014) (289)
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. (2011) (280)
Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias (2011) (278)
Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease (2008) (272)
Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease (2013) (270)
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions (2018) (266)
Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease (2007) (255)
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. (2012) (244)
Combined PET/CT Imaging in Oncology. Impact on Patient Management. (2000) (237)
Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease (2013) (235)
β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia (2010) (232)
Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. (2014) (228)
Suspected non-Alzheimer disease pathophysiology — concept and controversy (2016) (224)
Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics (2006) (221)
The 18F-FDG PET Cingulate Island Sign and Comparison to 123I-β-CIT SPECT for Diagnosis of Dementia with Lewy Bodies (2009) (214)
Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing (2013) (207)
Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (2013) (198)
Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations (2013) (198)
High performance plasma amyloid-beta biomarkers for Alzheimer's disease (2018) (197)
Brain Amyloid Imaging (2011) (191)
Cerebral quantitative susceptibility mapping predicts amyloid-&bgr;-related cognitive decline (2017) (185)
The Amyloid-β Pathway in Alzheimer’s Disease (2021) (185)
Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. (2014) (183)
Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study (2016) (182)
Plasma apolipoprotein E and Alzheimer disease risk (2011) (182)
Image Analysis in Patients with Cancer Studied with a Combined PET and CT Scanner (2000) (180)
Fibre-specific white matter reductions in Alzheimer’s disease and mild cognitive impairment (2018) (177)
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease (2012) (175)
In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease (2014) (167)
High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. (2009) (163)
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias (2020) (163)
Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition (2012) (163)
Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. (2013) (162)
In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies (2007) (159)
Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study (2011) (153)
Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study. (2015) (151)
11C-PIB binding is increased in patients with cerebral amyloid angiopathy–related hemorrhage (2010) (149)
Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) (145)
Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. (2011) (142)
Larger temporal volume in elderly with high versus low beta-amyloid deposition. (2010) (140)
Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts (2018) (140)
Head-to-Head Comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-Amyloid Imaging in Aging and Dementia (2013) (138)
The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease (2012) (136)
Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age (2013) (136)
Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. (2010) (125)
Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer’s disease (2019) (123)
Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease (2016) (121)
Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease (2011) (121)
Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease (2014) (121)
Incidence of cerebral microbleeds in preclinical Alzheimer disease (2014) (120)
Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology (2018) (118)
In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133 (2010) (116)
Association of Cerebral Amyloid-&bgr; Aggregation With Cognitive Functioning in Persons Without Dementia (2018) (116)
Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease (2020) (115)
Four-repeat tauopathies (2019) (115)
APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease (2014) (113)
A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study (2014) (110)
Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults (2012) (109)
Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals (2017) (109)
Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia (2018) (107)
Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias (2009) (106)
In vivo tau imaging: Obstacles and progress (2014) (106)
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease (2013) (105)
The Relationship between Sleep Quality and Brain Amyloid Burden. (2016) (100)
Implementation and Validation of an Adaptive Template Registration Method for 18F-Flutemetamol Imaging Data (2013) (99)
Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s disease (2014) (98)
The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias (2008) (97)
Comparison of MR-less PiB SUVR quantification methods (2015) (97)
In Vivo Measurement of Dopamine Receptors in Human Brain by Positron Emission Tomography Age and Sex Differences a (1988) (97)
Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy (2020) (94)
Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer’s Disease: A Preliminary Study (2014) (93)
Localization of serotonin 5‐HT2 receptors in living human brain by positron emission tomography using N1‐([11C]‐methyl)‐2‐BR‐LSD (1987) (93)
Biochemically-defined pools of amyloid-&bgr; in sporadic Alzheimer’s disease: correlation with amyloid PET (2017) (91)
Aβ-amyloid and Tau Imaging in Dementia. (2017) (90)
Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. (2011) (88)
Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS). (2013) (88)
Risk prediction of late-onset Alzheimer’s disease implies an oligogenic architecture (2020) (86)
Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study (2014) (86)
The challenges of tau imaging (2012) (86)
Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. (2007) (86)
In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. (2009) (85)
Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging (2008) (80)
Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies (2018) (79)
Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease (2014) (79)
Diagnostic imaging agents for Alzheimer's disease: copper radiopharmaceuticals that target Aβ plaques. (2013) (78)
In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106 (2013) (77)
18F-Florbetaben PET beta-amyloid binding expressed in Centiloids (2017) (77)
Radiation Dosimetry of β-Amyloid Tracers 11C-PiB and 18F-BAY94-9172 (2009) (76)
Blood-Borne Amyloid-β Dimer Correlates with Clinical Markers of Alzheimer's Disease (2010) (76)
Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (2015) (75)
Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples (2013) (74)
Radioiodinated clioquinol as a biomarker for β‐amyloid: Zn2+ complexes in Alzheimer's disease (2006) (74)
Evaluating image reconstruction methods for tumor detection in 3-dimensional whole-body PET oncology imaging. (2003) (74)
Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies (2014) (74)
Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score (2015) (72)
Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden (2018) (72)
Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon. (1999) (69)
11C-PiB PET studies in typical sporadic Creutzfeldt–Jakob disease (2009) (68)
APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease (2015) (67)
An increased neutrophil–lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation (2014) (67)
Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale (2016) (66)
Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease (2013) (66)
Olfactory deficits and amyloid-β burden in Alzheimer's disease, mild cognitive impairment, and healthy aging: a PiB PET study. (2011) (64)
Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. (2016) (63)
Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions (2016) (63)
Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis (2020) (62)
Association of &bgr;-Amyloid and Apolipoprotein E &egr;4 With Memory Decline in Preclinical Alzheimer Disease (2018) (61)
Brain amyloid imaging. (2013) (61)
Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease. (2010) (60)
Influence of BDNF Val66Met on the relationship between physical activity and brain volume (2014) (60)
Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. (2014) (59)
Imaging nicotinic acetylcholine receptors with fluorine-18-FPH, an epibatidine analog. (1997) (59)
A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease (2019) (59)
The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. (2006) (58)
Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target? (2014) (58)
Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease (2019) (57)
Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative (2010) (57)
Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. (1997) (57)
A copper radiopharmaceutical for diagnostic imaging of Alzheimer's disease: a bis(thiosemicarbazonato)copper(II) complex that binds to amyloid-beta plaques. (2010) (56)
Relationship between nicotinic receptors and cognitive function in early Alzheimer’s disease: A 2-[18F]fluoro-A-85380 PET study (2008) (55)
Amyloid burden and incident depressive symptoms in cognitively normal older adults (2017) (55)
Amyloid imaging with PET in early Alzheimer disease diagnosis. (2013) (55)
A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study (2017) (54)
Rapid decline in episodic memory in healthy older adults with high amyloid-β. (2013) (53)
Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease (2005) (53)
An analytic study of the effects of attenuation on tumor detection in whole-body PET oncology imaging. (2003) (52)
Aβ amyloid, cognition, and APOE genotype in healthy older adults (2013) (52)
18F-florbetaben Aβ imaging in mild cognitive impairment (2013) (52)
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease (2012) (52)
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease (2017) (52)
MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET (2014) (51)
In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer. (2012) (50)
[125/123I]IPH: A radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors (1997) (49)
Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer's disease. (2011) (49)
Plasma Cortisol, Brain Amyloid-β, and Cognitive Decline in Preclinical Alzheimer's Disease: A 6-Year Prospective Cohort Study. (2017) (49)
Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. (2015) (48)
Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods (2018) (47)
Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. (2013) (47)
Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease (2017) (47)
Relationship between Memory Performance and β-Amyloid Deposition at Different Stages of Alzheimer’s Disease (2012) (46)
18 F-THK 523 : a novel in vivo tau imaging ligand for Alzheimer ’ s disease (2011) (46)
Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials (2013) (46)
Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group (2016) (46)
Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer’s disease (2020) (45)
Clinical Profile of PiB-Positive Corticobasal Syndrome (2013) (45)
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
Intravenous Nicotine Reduces Cerebral Glucose Metabolism: A Preliminary Study (2003) (44)
Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD (2019) (44)
Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Aβ accumulation in cognitively normal older adults and adults with MCI. (2015) (44)
Amyloid imaging: Past, present and future perspectives (2016) (43)
Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults (2017) (43)
Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET. (2005) (43)
Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using F-THK5105 PET (2014) (43)
Engineered antibodies: new possibilities for brain PET? (2019) (42)
Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden. (2015) (42)
Decline in cognitive function over 18 months in healthy older adults with high amyloid-β. (2013) (42)
Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer’s disease (2016) (41)
Differential Diagnosis in Alzheimer’s Disease and Dementia with Lewy Bodies via VMAT2 and Amyloid Imaging (2012) (41)
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease (2021) (41)
Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease (2020) (41)
Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease. (2015) (41)
Asymmetric thinning of the cerebral cortex across the adult lifespan is accelerated in Alzheimer’s disease (2020) (41)
Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. (2014) (40)
Mediterranean diet adherence and rate of cerebral Aβ-amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (2018) (40)
Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes (2017) (40)
b -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease (2007) (39)
Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease (2021) (39)
Risk of Alzheimer's Disease in Obstructive Sleep Apnea Syndrome: Amyloid-β and Tau Imaging. (2018) (39)
Episodic memory decline predicts cortical amyloid status in community-dwelling older adults. (2011) (38)
Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing. (2012) (38)
Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology (2019) (37)
A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer’s Disease (2016) (37)
MR atlas of the baboon brain for functional neuroimaging (2002) (37)
Subacute Ischemic Stroke Is Associated With Focal 11C PiB Positron Emission Tomography Retention But Not With Global Neocortical A&bgr; Deposition (2012) (36)
Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests. (2012) (36)
Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) (2013) (36)
Amyloid-Related Memory Decline in Preclinical Alzheimer’s Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months (2015) (36)
In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease. (2011) (36)
In vivo labeling of the dopamine D2 receptor with N-11C-methyl-benperidol. (1990) (36)
Differentiating the frontal presentation of Alzheimer's disease with FDG-PET. (2015) (36)
Non-Verbal Episodic Memory Deficits in Primary Progressive Aphasias are Highly Predictive of Underlying Amyloid Pathology. (2016) (35)
The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis (2016) (35)
Computer-aided detection of cerebral microbleeds in susceptibility-weighted imaging (2015) (34)
OPTIMAL REFERENCE REGION TO MEASURE LONGITUDINAL AMYLOID-BETA CHANGE WITH 18F-FLORBETABEN PET (2016) (34)
Long night's journey into the day: amyloid-β imaging in Alzheimer's disease. (2012) (34)
Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease. (2013) (34)
Cerebral β‐amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator‐related hemorrhage (2010) (33)
Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging (2015) (32)
Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. (2017) (32)
[18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia (2017) (31)
Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study (2014) (30)
Imaging histamine H1 receptors in the living human brain with carbon-11-pyrilamine. (1991) (30)
Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial (2020) (29)
Neuroimaging biomarkers in Alzheimer’s disease and other dementias (2016) (29)
KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden (2018) (29)
A Multi-Cohort Study of ApoE ɛ4 and Amyloid-β Effects on the Hippocampus in Alzheimer’s Disease (2017) (29)
Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-β: prodromal Alzheimer's disease? (2013) (29)
Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort (2017) (29)
Amyloid Imaging in Alzheimer’s Disease and Other Dementias (2009) (28)
The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI (2013) (28)
Predicting Alzheimer disease from a blood-based biomarker profile (2016) (28)
Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury (2020) (28)
Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer's disease (2020) (28)
Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation (2020) (27)
Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid-β. (2018) (26)
Efficient machine learning framework for computer-aided detection of cerebral microbleeds using the Radon transform (2014) (25)
Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals (2020) (25)
Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. (2018) (25)
Automated (11)C-PiB standardized uptake value ratio. (2008) (25)
Galantamine-induced improvements in cognitive function are not related to alterations in α4β2 nicotinic receptors in early Alzheimer’s disease as measured in vivo by 2-[18F]Fluoro-A-85380 PET (2008) (25)
Amyloid-β: the seeds of darkness. (2011) (24)
Brain glucose metabolism in Rett Syndrome. (2002) (24)
Dopamine transporter changes in neuropsychiatric disorders. (1998) (24)
Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. (2018) (24)
Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness (2017) (24)
Cortical [18F]PI‐2620 Binding Differentiates Corticobasal Syndrome Subtypes (2021) (24)
Sequential H(2)(15)O PET studies in baboons: before and after amphetamine. (2002) (24)
RETINAL AMYLOID FLUORESCENCE IMAGING PREDICTS CEREBRAL AMYLOID BURDEN AND ALZHEIMER'S DISEASE (2014) (23)
Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease using Cerebrospinal Fluid Biomarkers in the AIBL Study (2019) (23)
Pupil response biomarkers for early detection and monitoring of Alzheimer's disease. (2013) (23)
Positron Emission Tomographic Imaging in Stroke (2015) (23)
18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias (2015) (23)
Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging (2020) (23)
MR-Less High Dimensional Spatial Normalization of 11C PiB PET Images on a Population of Elderly, Mild Cognitive Impaired and Alzheimer Disease Patients (2008) (23)
Metals, membranes, and amyloid-β oligomers: key pieces in the Alzheimer's disease puzzle? (2012) (23)
Amyloid PET Ligands for Dementia. (2010) (22)
Relationship between amyloid and tau levels and its impact on tau spreading (2021) (22)
Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. (2017) (22)
Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis (2016) (22)
A&bgr;-related memory decline in APOE &egr;4 noncarriers: Implications for Alzheimer disease (2016) (22)
Cerebral Blood Flow and Aβ-Amyloid Estimates by WARM Analysis of [11C]PiB Uptake Distinguish among and between Neurodegenerative Disorders and Aging (2017) (21)
Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition (2020) (21)
Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer’s disease (2018) (21)
A ‘Disease Severity Index’ to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia (2017) (21)
PET studies of cerebral glucose metabolism: acute effects of cocaine and long-term deficits in brains of drug abusers. (1996) (21)
A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort (2017) (21)
Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects (2021) (21)
Klotho allele status is not associated with Aβ and APOE ε4–related cognitive decline in preclinical Alzheimer's disease (2019) (21)
Trajectories of depressive and anxiety symptoms in older adults: a 6‐year prospective cohort study (2018) (20)
18 F-florbetaben Ab imaging in mild cognitive impairment (2013) (20)
BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF (2017) (19)
Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease. (2020) (19)
Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography. (2018) (19)
Radiolabeled neuronal nitric oxide synthase inhibitors: synthesis, in vivo evaluation, and primate PET studies. (2000) (18)
Positron Emission Tomographic Imaging in Stroke Cross-Sectional and Follow-Up Assessment of Amyloid in Ischemic Stroke (2015) (18)
Effect of Structural Modifications to Glyoxal-bis(thiosemicarbazonato)copper(II) Complexes on Cellular Copper Uptake, Copper-Mediated ATP7A Trafficking, and P-Glycoprotein Mediated Efflux. (2018) (18)
Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease (2020) (18)
β-Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men. (2016) (18)
Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer’s disease (2021) (17)
Relationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. (2018) (17)
Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults (2020) (17)
Advances in Brain Amyloid Imaging. (2021) (17)
Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET (2021) (17)
A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer’s Disease (2018) (17)
Computational analysis of PET by AIBL (CapAIBL): a cloud-based processing pipeline for the quantification of PET images (2015) (16)
The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update (2021) (16)
Severe Obstructive Sleep Apnea Is Associated with Higher Brain Amyloid Burden: A Preliminary PET Imaging Study. (2020) (16)
Peripheral α-defensins 1 and 2 are elevated in Alzheimer's disease. (2015) (16)
Peptide T and glucose metabolism in AIDS dementia complex. (1996) (16)
Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults. (2018) (16)
Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: An update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study (2013) (16)
Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease. (2011) (16)
Rhenium and technetium complexes that bind to amyloid-β plaques. (2015) (16)
Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease (2022) (16)
Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology (2020) (16)
In vivo microstructural heterogeneity of white matter lesions in healthy elderly and Alzheimer's disease participants using tissue compositional analysis of diffusion MRI data (2020) (15)
The Tau MeTeR composites for the generation of continuous and categorical measures of tau deposits in the brain (2017) (15)
Constructing longitudinal disease progression curves using sparse, short‐term individual data with an application to Alzheimer's disease (2017) (15)
Rates of age- and amyloid β-associated cortical atrophy in older adults with superior memory performance (2019) (15)
Influence of Comorbidity of Cerebrovascular Disease and Amyloid-β on Alzheimer's Disease. (2019) (15)
Neuropsychology and neuroimaging profiles of amyloid-positive versus amyloid-negative amnestic mild cognitive impairment patients (2018) (15)
Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer’s Disease (2020) (15)
11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): a case report. (2010) (15)
Management Impact of Imaging Brain Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian Syndrome with 18F-AV133 and PET (2017) (15)
Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia (2016) (14)
Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study (2019) (14)
Radiation Dosimetry of b-Amyloid Tracers 11 C-PiB and 18 F-BAY94-9172 (2009) (14)
OPTIMAL REFERENCE REGION TO MEASURE LONGITUDINAL AMYLOID-BETA CHANGE WITH 18F-FLORBETABEN PET (2016) (14)
Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults. (2019) (14)
Molecular Imaging Approaches in Dementia. (2021) (14)
Tau deposition patterns are associated with functional connectivity in primary tauopathies (2022) (14)
Alzheimer disease: The landscape of ageing—insights from AD imaging markers (2014) (14)
Advances in molecular imaging for the diagnosis of dementia. (2009) (14)
Validation of a priori candidate Alzheimer’s disease SNPs with brain amyloid-beta deposition (2019) (14)
What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies (2020) (14)
Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral Aβ-Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study (2021) (13)
Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease. (2018) (13)
Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-β–negative cognitively normal individuals (2020) (13)
Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy (2021) (13)
The preparation of 123/125I‐clioquinol for the study of Aβ protein in Alzheimer's disease (2005) (13)
Case Report: 18F-MK6240 Tau Positron Emission Tomography Pattern Resembling Chronic Traumatic Encephalopathy in a Retired Australian Rules Football Player (2020) (13)
Effect of BDNF Val 66 Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer ’ s Disease : A Preliminary Study (2014) (13)
[18F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment (2019) (13)
Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease (2018) (12)
PIB-PET SEGMENTATION FOR AUTOMATIC SUVR NORMALISATION WITHOUT MR INFORMATION (2007) (12)
[125]I-spectramide: a novel benzamide displaying potent and selective effects at the D2 dopamine receptor. (1989) (12)
Relationship between Atrophy and Beta-Amyloid Deposition in Normal Elderly, Mild Cognitive Impairment and Alzheimer's Disease (2010) (12)
Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study (2019) (12)
Targeting metals rescues the phenotype in an animal model of tauopathy. (2018) (12)
Synthesis of Oxorhenium(V) and Oxotechnetium(V) Complexes That Bind to Amyloid-β Plaques. (2016) (12)
La Lunga Attesa: Towards a Molecular Approach to Neuroimaging and Therapeutics in Alzheimer's Disease (2006) (12)
Chronic stress and Alzheimer's disease: the interplay between the hypothalamic–pituitary–adrenal axis, genetics and microglia (2021) (12)
Longitudinal evaluation of the natural history of amyloid-β in plasma and brain (2020) (12)
Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. (2022) (12)
Comparison of [11C]diprenorphine and [11C]carfentanil in vivo binding to opiate receptors in man using a dual detector system. (1994) (11)
Automatic detection of small spherical lesions using multiscale approach in 3D medical images (2013) (11)
Tractographic Threshold-Free Cluster Enhancement : Whole-Brain Statistical Analysis of Diffusion MRI Measures in the Presence of Crossing Fibres (2012) (11)
IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA. Authors' reply (2008) (11)
Aβ-related memory decline in APOE ε4 noncarriers (2016) (11)
Characteristics of subjective cognitive decline associated with amyloid positivity (2021) (10)
The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults (2018) (10)
Early detection of amyloid load using 18F-florbetaben PET (2021) (10)
Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI (2021) (10)
Spline Based Inhomogeneity Correction for 11C-PIB PET Segmentation Using Expectation Maximization (2007) (9)
Tau imaging with PET: an overview of challenges, current progress, and future applications. (2017) (9)
CapAIBL: Automated Reporting of Cortical PET Quantification Without Need of MRI on Brain Surface Using a Patch-Based Method (2016) (9)
A beta-amyloid and Tau Imaging in Dementia (2017) (9)
Local intensity model: An outlier detection framework with applications to white matter hyperintensity segmentation (2011) (9)
The Aβcentric Pathway of Alzheimer’s Disease (2007) (9)
Research and applications: MilxXplore: a web-based system to explore large imaging datasets (2013) (9)
Amyloid imaging in therapeutic trials: The quest for the optimal reference region (2015) (9)
Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease (2022) (9)
Sensitivity of a Preclinical Alzheimer’s Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer’s disease (2019) (9)
AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON THE BRAIN SURFACE (2019) (9)
Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients (2018) (9)
In vivo tau imaging in Alzheimer's disease and other dementias (2012) (8)
Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease (2020) (8)
Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults (2014) (8)
Voyage au bout de la nuit: Aβ and tau imaging in dementias. (2014) (8)
APOEɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. (2017) (8)
Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease (2021) (8)
Imaging of Reactive Astrogliosis by Positron Emission Tomography (2022) (7)
Baseline White Matter Is Associated With Physical Fitness Change in Preclinical Alzheimer’s Disease (2020) (7)
The exception makes the rule (2012) (7)
Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism (2020) (7)
EVALUATION OF [F-18]-PI-2620, A SECOND-GENERATION SELECTIVE TAU TRACER, FOR THE ASSESSMENT OF ALZHEIMER’S AND NON-ALZHEIMER’S TAUOPATHIES (2018) (7)
Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum (2022) (7)
AIBL (Australian Imaging, Biomarkers and Lifestyle) flagship study of aging (2009) (7)
Author Correction: Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions (2018) (7)
In vivo microstructural heterogeneity of white matter lesions in Alzheimer’s disease using tissue compositional analysis of diffusion MRI data (2019) (7)
Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies (2020) (7)
Imago Mundi, Imago AD, Imago ADNI (2014) (7)
Assessment of Aβ Deposition in Mild Cognitive Impairment with 18F-Florbetaben (2010) (7)
Safety of Disclosing Amyloid Imaging Results to MCI and AD Patients (2017) (7)
PREDICTING ALZHEIMER'S DISEASE FROM A BLOOD-BASED BIOMARKER PROFILE: RESULTS FROM AIPL AT 54 MONTHS (2014) (7)
II.P13 Amyloid load in Parkinson's Disease Dementia (PDD) and Lewy Body Dementia (LBD) measured with 11C-PIB PET (2006) (7)
Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume (2022) (6)
Toward a Universal Readout for 18F-Labeled Amyloid Tracers: The CAPTAINs Study (2021) (6)
Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer’s Disease Patients and Correlates with Cognitive Performance (2020) (6)
Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group (2016) (6)
FDG-PET: A sensitive tool for the localization of MIBG-negative pelvic pheochromocytomas (1998) (6)
Age dependent prevalence of beta-amyloid positive 11C-PiB PET in healthy elderly subjects parallels neuropathology findings (2008) (6)
Exploiting the Full Potential of β-Amyloid and Tau PET Imaging for Drug Efficacy Testing (2020) (6)
Advances in structural and molecular neuroimaging in Alzheimer's disease (2011) (6)
D2 DOPAMINE RECEPTORS IN TOURETTEʼS SYNDROME AND MANIC DEPRESSIVE ILLNESS (1988) (6)
Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort (2022) (6)
APOE ε2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies (2022) (6)
A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials (2019) (6)
A simple probe measures the pharmacokinetics of[125I]RTI-55 in mouse brain in vivo. (1997) (6)
Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume (2022) (6)
Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: Predictive value of Aβ imaging with 18F-Florbetaben (2011) (6)
18F-Florbetaben (FBB) PET SUVR quantification: Which reference region? (2015) (6)
Head-to-head comparison of 11C-PiB and 18F-AZD4694 for beta-amyloid imaging in aging and dementia (2012) (5)
Effects of attenuation correction on tumor detection in PET oncology (2000) (5)
PET Imaging of brain muscarinic receptors with 18F-Fluorobenzyl-Dexetimide: A first in human study (2021) (5)
Amyloid-β, Tau, and 18F-Fluorodeoxyglucose Positron Emission Tomography in Posttraumatic Stress Disorder. (2019) (5)
Not all A plaques are created equal (2012) (5)
COMT val158met is not associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal older adults (2019) (5)
First results from human studies of a novel F-18 PET ligand for brain {beta}-amyloid imaging (2007) (5)
A head-to-head comparison of cerebral blood flow SPECT and 18 F-FDG PET in the diagnosis of Alzheimer's Disease. (2020) (5)
Self-reported confusion is related to global and regional β-amyloid: data from the Women’s healthy ageing project (2018) (5)
AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON BRAIN SURFACE (2019) (5)
IN VIVO IMAGING OF BRAIN MUSCARINIC RECEPTORS WITH 18F-FLUROBENZYL DEXETIMIDE: FIRST IN HUMAN STUDIES (2019) (5)
PET-only 18F-AV1451 tau quantification (2017) (5)
11C-PIB PET imaging in the differential diagnosis of dementia (2006) (5)
Aβ amyloid, cognition and APOE genotype in the preclinical stages of Alzheimer's disease (2012) (5)
Novel fluorine-18 labeled 2-arylquinoline derivatives for imaging tau-pathology in Alzheimer's disease (2012) (4)
A Copper Radiopharmaceutical for Diagnostic Imaging of Alzheimer′s Disease: A Bis(thiosemicarbazonato)copper(II) Complex That Binds to Amyloid‐β Plaques. (2010) (4)
The natural history of the dynamics of beta-amyloid deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease (2013) (4)
MR-Less Surface-Based Amyloid Estimation by Subject-Specific Atlas Selection and Bayesian Fusion (2012) (4)
Amyloid-beta: The seeds of darkness (2011) (4)
D2 dopamine receptors in drug naive schizophrenics: update on 20 subjects (1989) (4)
Quantitative approaches to amyloid imaging. (2011) (4)
Reduced cortical cholinergic innervation measured using [18F]-FEOBV PET imaging correlates with cognitive decline in mild cognitive impairment (2022) (4)
A normalisation framework for quantitative brain imaging; application to quantitative susceptibility mapping (2017) (4)
Generative atlases and atlas selection for C11-PIB PET-PET registration of elderly, mild cognitive impaired and Alzheimer disease patients (2008) (4)
Aβ Imaging in Aging, Alzheimer’s Disease and Other Neurodegenerative Conditions (2014) (4)
Untangling tau imaging (2016) (4)
AT(N) predicts near-term development of Alzheimer's disease symptoms in unimpaired older adults (2022) (4)
Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis (European Journal of Nuclear Medicine and Molecular Imaging, (2017), 44, 3, (353-357), 10.1007/s00259-016-3589-9) (2017) (4)
Plasma glial ﬁ brillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer ’ s disease (2021) (4)
Manifold drived MR-less PiB SUVR normalisation (2012) (4)
Generating continuous and categorical measures from tau imaging studies with 18F-AV1451 and 18F-THK5351: The Tau MeTeR scale (2016) (4)
Update on PET methods for D2 dopamine receptors in schizophrenia and bipolar disorder (1989) (4)
Anti-Aβ antibody target engagement: a response to Siemers et al. (2014) (4)
Investigating the synergistic relationship between sleep quality, physical activity, and levels of brain beta-amyloid (2015) (4)
Microbleeds and clinical trajectories: Results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging (2013) (4)
Mesial temporal tau in amyloid-β-negative cognitively normal older persons (2022) (4)
Rare genetically defined causes of dementia (2005) (4)
The heritability of amyloid burden in older adults: the Older Australian Twins Study (2021) (3)
In vivo pattern of tau and beta-amyloid deposition in the brain might distinguish healthy individuals from those with preclinical Alzheimer's disease (2013) (3)
CORRELATION OF AMYLOID PET EXPRESSED IN CENTILOID UNITS WITH NEUROPATHOLOGICAL FINDINGS IN ALZHEIMER’S DISEASE (2018) (3)
Neutrophil-lymphocyte ratio in Alzheimer's disease: Data from the Australian Imaging Biomarker and Lifestyle study of ageing (2013) (3)
Genetic risk for attention-deficit/hyperactivity disorder predicts cognitive decline and development of Alzheimer’s disease pathophysiology in cognitively unimpaired older adults (2022) (3)
Future Directions in Molecular Imaging of Neurodegenerative Disorders. (2022) (3)
18F-Florbetaben-pet imaging in the differential diagnosis of dementia (2010) (3)
Head‐to‐head comparison of cerebral blood flow single‐photon emission computed tomography and 18F‐fluoro‐2‐deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease (2021) (3)
F-florbetaben A β imaging in mild cognitive impairment (2013) (3)
Larger temporal volume in asymptomatic elderly with high versus low beta-amyloid deposition (2010) (3)
Predictors of cognitive decline at 18 month follow up among 1112 participants in the Australian imaging, biomarkers and lifestyle flagship study of ageing (AIBL) (2011) (3)
Divergent Network Patterns of Amyloid-β Deposition in Logopenic and Amnestic Alzheimer's Disease Presentations. (2016) (3)
The dawn of robust individualised risk models for dementia (2019) (3)
Comorbidity of Cerebrovascular and Alzheimer's Disease in Aging. (2020) (3)
Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer’s Disease (2022) (3)
THE TAU METER SCALE FOR THE GENERATION OF CONTINUOUS AND CATEGORICAL MEASURES OF TAU DEPOSITS IN THE BRAIN: RESULTS FROM 18F-AV1451 AND 18F-THK5351 TAU IMAGING STUDIES (2016) (3)
Can amyloid PET differentiate “pure” LBD from AD with or without LBD copathology? (2019) (3)
Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease? (2018) (3)
11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous. (2021) (3)
Effects of extracellular acetylcholine on muscarinic receptor binding assessed by [125I]dexetimide and a simple probe. (1998) (3)
Aβ accumulation in non-demented individuals: A longitudinal F-18-flutemetamol study (2015) (3)
Human biodistribution and internal dosimetry of 4-[ 18F]fluorobenzyl-dexetimide: a PET radiopharmaceutical for imaging muscarinic acetylcholine receptors in the brain and heart (2020) (3)
Variability in blood-based beta-amyloid assays: The need for consensus on preanalytical processing (2012) (3)
In vivo tau imaging in Alzheimer's disease and other dementias (2012) (3)
β-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3 (2022) (3)
Characterisation of [18F]-THK523, a novel in vivo tau imaging ligand (2010) (2)
Beta-amyloid imaging and memory in a large cohort of elderly individuals (2008) (2)
β-amyloid in biological samples: not all Aβ detection methods are created equal (2014) (2)
OPL204 Amyloid imaging in Lewy Body Dementia with 11C-PIB-PET (2005) (2)
THE ASSOCIATION BETWEEN AMYLOID BURDEN AND SUB-CLINICAL DEPRESSION IN HEALTHY OLDER ADULTS (2014) (2)
Cognitive consequences of high beta-amyloid levels in people with mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer's disease (2013) (2)
Nicotinic receptor imaging with 2-[18F]F-A-85380 PET does not differentiate early Alzheimer's disease patients from healthy controls (2007) (2)
Serotonin Transporter Binding In Vivo (2001) (2)
18F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy (2022) (2)
Supervised method to build an atlas database for multi-atlas segmentation-propagation (2010) (2)
CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS (2014) (2)
Biomarker-based prediction of cognitive decline in 270 nondemented older individuals: Three-year follow-up results from the Australian Imaging Biomarkers and Lifestyle study of Aging (AIBL) (2013) (2)
Rates of conversion to MCI and Alzheimer's in the Australian Imaging, Biomarkers and Lifestyle (AIBL) cohort over 36 months (2012) (2)
0 Effects of Attenuation on Tumor Detection in PET Oncology (2001) (2)
Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease (2022) (2)
Alzheimer’s disease biomarker roadmap 2020: Fluid biomarkers (2020) (2)
Alzheimer’s disease biomarker roadmap 2020: Second‐generation tau PET tracers (2020) (2)
18F‐MK6240 longitudinal tau PET in ageing and Alzheimer’s disease (2021) (2)
Automatic Detection of Cerebral Microbleed in SWI Using Radon Transform (2013) (2)
Rates of regional tau accumulation in ageing and across the Alzheimer's disease continuum: an AIBL 18F-MK6240 PET study (2022) (2)
CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS (2014) (2)
AMYLOID β-RELATED COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE IS MODERATED BY APOE AND BDNF POLYMORPHISMS (2014) (2)
O3-06-07 C-11 PIB PET amyloid imaging in aging and dementia (2006) (2)
MESIAL TEMPORAL TAU BURDEN IN OLDER ADULTS WITH SUBJECTIVE MEMORY COMPLAINTS RELATES TO POORER MEMORY FUNCTION (2016) (2)
Combining PIB and FDG PET data to distinguish AD patients from normal controls: A multi-modal partial least square approach (2008) (2)
Elevated PiB precedes dementia in autosomal dominant Alzheimer's disease: PiB, FDG and atrophy in the DIAN cohort (2012) (2)
Alzheimer's disease detection using 11C-PiB with improved partial volume effect correction (2009) (2)
Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: Predictive value of Aβ imaging with 18F-Florbetaben (2011) (2)
The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults (2022) (2)
Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer’s Disease (2022) (2)
Atrophy , hypometabolism and clinical trajectories in amyloid negative probable AD patients (2018) (2)
Cognition, hippocampal volume and fibrillar Aβ burden as predictors of cognitive decline: Three-year follow-up results from AIBL (2012) (2)
Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition (2021) (2)
D2 dopamine receptors increased in psychotic, but not non-psychotic affective disorder (1989) (2)
Cross-sectional and Longitudinal Analysis of the Relationship Between A β Deposition , Cortical Thickness , andMemory in Cognitively Unimpaired Individuals and in Alzheimer Disease (2013) (2)
Apparent fibre density: A novel MRI approach that identifies specific white matter tracts affected in Alzheimer's disease and MCI (2012) (2)
DETECTION OF PRODROMAL ALZHEIMER'S DISEASE WITH 18F-FLORBETABEN Aβ IMAGING: A PROSPECTIVE OUTCOME STUDY (2014) (2)
A surface based approach for cortical thickness comparison between PiB+ and PiB- healthy control subjects (2012) (2)
TO TAU OR TO MAO-B? MOST OF THE [F-18]-THK5351 SIGNAL IS BLOCKED BY SELEGILINE (2018) (2)
The biomarker roadmap for the validation for Alzheimer’s biomarkers: Methodological update for biomarkers of tauopathy (2020) (2)
Proceedings of the International Society for Magnetic Resonance in Medicine. Salt Lake City, Utah, USA (2013) (2)
Amyloid imaging (2011) (2)
Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis (2016) (2)
Exploring discordant low amyloid beta and high neocortical tau positron emission tomography cases (2022) (2)
Amyloid imaging in Alzheimer's disease: Relationships to memory deficits, brain atrophy, and hypometabolism (2012) (2)
O1-04-03 Amyloid burden in ageing subjects with and without cognitive decline (2007) (2)
The interaction between physical activity and sleep on cognitive function and brain beta-amyloid in older adults (2022) (2)
Association between amyloid-beta deposition and cortical thickness in dementia with Lewy bodies (2022) (1)
Mediterranean diet adherence is associated with less cerebral amyloid accumulation over time: Data from the australian imaging, biomarkers, and lifestyle study of ageing (2015) (1)
New developments in molecular imaging of the pathology of neurodegeneration (2014) (1)
COMPARISON OF 18F-FLORBETABEN QUANTIFICATION RESULTS USING MR-BASED AND MR-LESS CAPAIBL: VALIDATION AGAINST HISTOPATHOLOGY (2017) (1)
Elevated levels of synaptic protein GAP‐43 associate with brain tauopathy, atrophy and cognition in Alzheimer’s disease (2020) (1)
Correlating the frontal presentation of Alzheimer's disease with frontal metabolism as measured by FDG-PET (2012) (1)
The effect of vascular risk factors on cognition in older adults: Data from the AIBL study (2012) (1)
P2-317 In vitro characterization of PIB binding to α-synuclein (2006) (1)
Multimodality Imaging Population Analysis using Manifold Learning (2011) (1)
Dynamic of Beta-amyloid deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a PiB-PET longitudinal study (2011) (1)
Diminished white matter integrity four decades after traumatic brain injury in Vietnam War veterans (2021) (1)
Aβ accumulation correlates with cognitive decline: results from the longitudinal AIBL study (2011) (1)
The AIBL study: Baseline data from a multicenter, prospective longitudinal study of ageing in 1,100 volunteers (2009) (1)
Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging (2020) (1)
Dynamic of beta-amyloid deposition in healthy elderly, mild cognitive impairment and alzheimer's disease: a PiB-PET longitudinal study (2011) (1)
IC-P3-226: Prevalence of Aβ positive 11C-PiB PET studies in healthy elderly subjects parallels neuropathology findings (2008) (1)
VISUAL ASSESSMENT OF β-AMYLOID PET SCAN IS IMPROVED BY CAPAIBL (2018) (1)
PTSD AND RISK OF ALZHEIMER’S DISEASE IN AUSTRALIAN VIETNAM VETERANS: AMYLOID AND TAU PET FINDINGS FROM AIBL-VETS (2017) (1)
Alzheimer’s disease biomarker roadmap 2020: [ 18 F]flortaucipir: Strategic roadmap for the translation of tau biomarkers in the clinic: An international task force (2020) (1)
ADVANCED DIFFUSION MRI ENABLES IN VIVO INVESTIGATION OF MICROSTRUCTURAL HETEROGENEITY OF WHITE MATTER HYPERINTENSITIES IN ALZHEIMER’S DISEASE (2018) (1)
Imago Mundi, Imago AD, Imago ADNI (2014) (1)
CEREBRAL BLOOD FLOW, OXYGEN AND GLUCOSE METABOLISM IN JEOPARDIZED CEREBRUM AFTER EXPERIMENTAL STROKE (1988) (1)
REVISITING, REVISING AND REFINING THE NATURAL HISTORY OF AB DEPOSITION AND ITS EFFECTS ON NEURODEGENERATION AND COGNITIVE DECLINE IN SPORADIC ALZHEIMER’S DISEASE (2016) (1)
Evaluation of the novel 18F‐labeled PET tracer SMBT‐1 for imaging astrogliosis in healthy elderly controls and A+/T+/(N+) Alzheimer's disease patients (2020) (1)
Cognitive change and Aβ deposition in MCI subjects studied with serial 18F-florbetaben PET over 2 years (2012) (1)
Novel CYP1B1-RMDN2 Alzheimers disease locus identified by genome-wide association analysis of cerebral tau deposition on PET (2023) (1)
Longitudinal assessment of A beta accumulation in non-demented individuals: A F-18-flutemetamol study (2015) (1)
Plasma p217+tau vs NAV4694 amyloid and MK6240 tau PET across the Alzheimer continuum. (2022) (1)
IMPLEMENTING THE CENTILOID TRANSFORMATION FOR 18F-FLORBETABEN AND 18F-NAV4694 USING CAPAIBL (2017) (1)
Relevance of a Truncated PRESENILIN 2 Transcript to Alzheimer's Disease and Neurodegeneration. (2021) (1)
A Framework to Objectively Identify Reference Regions for Normalizing Quantitative Imaging (2018) (1)
Relation between amyloid burden, brain atrophy and memory in Alzheimer's disease (2009) (1)
Early detection of amyloid load using 18F-florbetaben PET (2021) (1)
Comparisons of animal-human translated and human 18F-BAY94-9172 amyloid radiation dosimetry (2009) (1)
Comparison of 11C-PiB and 18F-AZD4694 for A{beta} imaging in ageing and dementia (2012) (1)
FIXEL-BASED ANALYSIS OF FIBRE TRACT DEGENERATION IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE (2017) (1)
Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real-world population-based cohort. (2023) (1)
Brain health correlates of mobility-related confidence (2022) (1)
FDG-PET improves diagnosis in patients presenting with focal onset variants of Alzheimer's disease (2014) (1)
From the CSIRO Preventative Health Flagship (1913) (1)
In vivo pattern of tau and beta-amyloid deposition in the brain might distinguish healthy controls from preclinical Alzheimer's disease (2013) (1)
IMPLEMENTING THE ATN CLASSIFICATION IN AIBL (2017) (1)
A data-derived Aβ biomarker model computed using longitudinal PIB data from AIBL (2012) (1)
In vivo quantification of striatal VMAT2 with [F-18] AV133 (2009) (1)
THE INFLUENCE OF LOW-DENSITY LIPOPROTEINS ON NEOCORTICAL AMYLOID LOAD IN THE AUSTRALIAN IMAGING BIOMARKER AND LIFESTYLE STUDY (2017) (1)
Interaction between 18F-THK5317, 18F-flutemetamol SUVR, and cortical thickness (2015) (1)
Progressive white matter abnormalities in autosomal dominant Alzheimer's disease: Results of the DIAN study (2012) (1)
IMPLEMENTING THE CENTILOID TRANSFORMATION FOR 18F-FLORBETABEN AND 18F-NAV4694 USING CAPAIBL (2017) (1)
EFFECTS OF MAPT OVER BRAIN GREY MATTER ATROPHY IN THE AIBL COHORT (2016) (1)
Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer’s disease pathology (2020) (1)
O1-04-06 Correlation of memory dysfunction and amyloid burden in mild cognitive impairment (2007) (1)
Plasma high‐density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume (2022) (1)
Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β (2022) (1)
Plasma beta-amyloid levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden (2013) (1)
Longitudinal analysis of cortical thickness in PiB+ and PiB- healthy elderly controls (2012) (1)
The effects of APOE4 on the rate of atrophy and Aβ deposition in asymptomatic elderly (2011) (1)
A longitudinal study of {beta}-amyloid deposition with 11C-PiB-PET (2008) (1)
Aβ accumulation correlates with cognitive decline: results from the longitudinal AIBL study (2011) (1)
Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer’s Disease (2023) (1)
THE CHALLENGES AHEAD FOR PET IMAGING OF PROGRESSIVE PROTEINOPATHIES (2016) (1)
Postmortem Neocortical 3H-PiB Binding and Levels of Unmodified and Pyroglutamate Aβ in Down Syndrome and Sporadic Alzheimer’s Disease (2021) (1)
Worster-Drought Syndrome (Familial British Dementia): A Case Report (2010) (1)
Correlation between white matter hyperintensities in MRI-FLAIR and 11C-PiB PET retention. A new potential for early identification of disease (2009) (1)
Comparing Amyloid PET Tracers and Interpretation Strategies: First Results from the CAPTAINs Study (2018) (1)
AN EXPLORATORY MOLECULAR IMAGING STUDY TARGETING Aβ WITH A NOVEL 8-OH QUINOLINE IN ALZHEIMER’S DISEASE (THE PBT2-204 IMAGINE STUDY) (2016) (1)
Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease (2022) (1)
Comparison of biomarkers for the prediction of cognitive decline (2010) (1)
Longitudinal analysis of cortical thickness in PiB+ and PiB- healthy elderly controls (2012) (1)
Genome‐wide study of the human lipidome and links to Alzheimer’s disease risk (2020) (1)
Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study (2022) (1)
PET image harmonization using smoothing-CycleGAN (2022) (1)
Using the Artificial Neural Network to discriminate between normal controls with different APOE e4 genotypes and probable AD cases in PIB-PET studies (2009) (1)
Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults (2017) (1)
DOES ENHANCED RECONSTRUCTION METHODOLOGY CHANGE THE QUANTIFICATION OF AMYLOID PET WITH FLUMETAMOL? (2014) (1)
ADVANCED DIFFUSION MRI ENABLES IN VIVO INVESTIGATION OF MICROSTRUCTURAL HETEROGENEITY OF WHITE MATTER HYPERINTENSITIES IN ALZHEIMER’S DISEASE (2018) (1)
The cognitive and brain volumetric trajectories of healthy elderly controls with either Alzheimer’s pathology, neurodegeneration (SNAP), or both (2015) (1)
Disentangling the interaction between amyloid and tau: where are we now? (2016) (1)
11C-PiB-postmortem Aβ plaque load correlation (2010) (1)
Additive value of [18F]PI-2620 perfusion imaging in four-repeat tauopathies (2022) (1)
Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease (2021) (1)
COGNITIVE SUPER-AGING VERSUS TYPICAL AGING IN COMMUNITY-DWELLING OLDER ADULTS: LONGITUDINAL TRAJECTORIES IN GLOBAL CORTICAL THICKNESS OVER SIX YEARS (2017) (1)
CenTauRz: A standardized quantification of tau PET scans (2022) (1)
FDG-PET improves diagnosis in patients presenting with focal onset dementias � (2015) (1)
Neuropsychological predictors of autobiographical memory impairment in mild cognitive impairment (MCI) (2013) (1)
A{beta} burden correlates with memory impairment in non-demented subjects but plateaus in established Alzheimer's disease: A PIB-PET cross sectional study (2007) (1)
AU‐ARROW (Australia) (2020) (1)
Gender-specific aging reductions in [11C-carbonyl] WAY100635 binding: Not an effect of atrophy (2000) (1)
P1-153: The relationship between olfactory identification and memory and Abeta burden in Alzheimer's disease, mild cognitive impairment and healthy aging: A PIB-PET study (2008) (1)
Assessing Aβ & tau pathology in Vietnam war veterans with chronic Post-Traumatic Stress Disorder (2016) (1)
GENETIC ANALYSIS OF THE STEROIDOGENESIS PATHWAY: ASSOCIATIONS WITH ALZHEIMER'S DISEASE RISK AND RELATED PHENOTYPES (2014) (1)
Alzheimer’s disease biomarker roadmap 2020: Time for tau (2020) (1)
HIGHER AB BURDEN IN HEALTHY APOE-E4 CARRIERS IS ASSOCIATED WITH SUBJECTIVE MEMORY COMPLAINTS: RESULTS FROM THE FLUTEMETAMOL AND PIB AIPL COHORTS (2014) (1)
81 In vivo tau imaging with PET (2012) (1)
CORRECTING FOR PET SCANNER CHANGES IN LONGITUDINAL STUDIES (2019) (1)
CONSIDERATION OF PRECLINICAL AD FROM THE PERSPECTIVE OF NORMAL AGING: AMYLOID-β RELATED CHANGES IN FLUID AND CRYSTALLIZED INTELLIGENCE IN A ROBUST SAMPLE OF HEALTHY OLDER ADULTS (2017) (1)
Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions (2020) (1)
18F‐PI‐2620 tau‐PET in corticobasal syndrome (ActiGliA cohort) (2020) (1)
Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF Aβ42 moderates the association between insulin resistance and increased CSF tau levels (2022) (1)
Galantamine improves cognitive performance without effecting nicotinic receptors in early Alzheimer's disease as measured by 2[18F]F-A-85380 PET (2007) (1)
COMPARISON OF 18F-FLORBETABEN QUANTIFICATION RESULTS USING MR-BASED AND MR-LESS CAPAIBL: VALIDATION AGAINST HISTOPATHOLOGY (2017) (1)
Pattern of A{beta} deposition in familial Alzheimer's disease is irrespective of mutation type or cognitive status (2008) (1)
Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease (2020) (1)
Biomarker-based prediction of cognitive decline in 270 nondemented older individuals: Three-year follow-up results from the Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL) (2013) (1)
GRAPHICAL NETWORK ANALYSES INFORMS PET Aβ-AMYLOID BIOMARKER DISCOVERY VIA QUANTIFICATION OF INDIVIDUAL PEPTIDE CONNECTIONS (2017) (1)
Ten-year MRI changes and FBB-PET: Results from the Women's Healthy Aging Project (WHAP) (2013) (1)
DETECTION OF PRODROMAL ALZHEIMER'S DISEASE WITH 18F-FLORBETABEN AB IMAGING: A PROSPECTIVE OUTCOME STUDY (2014) (1)
Focal Ab-amyloid deposition precedes cerebral microbleeds and Superficial siderosis: a case report (2017) (1)
Test-retest variability of [18F]BAY 94-9172 studies in Alzheimer's disease and normal ageing (2009) (1)
Registration of MRI - PET Images, Procedure and Validation (1988) (1)
Before and After Amphetamine (2002) (1)
P2-092: Prevalence of Aβ positive 11C-PiB PET studies in healthy elderly subjects parallels neuropathology findings (2008) (0)
Characterisation of Pittsburgh Compound-B (PIB) binding to white matter (2007) (0)
Imaging and cognitive biomarkers as predictors of progression to Alzheimer'S Disease (2012) (0)
[Introduction to positron emission tomography]. (1991) (0)
IN VIVO ASSESSMENT OF MARKERS OF ALZHEIMER’S DISEASE PATHOLOGY IN VIETNAM WAR VETERANS WITH CHRONIC POST-TRAUMATIC STRESS DISORDER (2016) (0)
AMYLOID-POSITIVE VERSUS -NEGATIVE AMCI: SIMILARITIES AND DIFFERENCES IN NEUROPSYCHOLOGY AND NEUROIMAGING PROFILES (2016) (0)
A voxel-based morphometry study of volumetric MRI in familial Alzheimer's disease (2012) (0)
Improved centiloid robustness using non‐negative matrix factorization (2020) (0)
Decreases in cerebral blood flow are associated with Aβ status in preclinical Alzheimer’s disease (2015) (0)
Towards a universal cortical tau sampling mask (2020) (0)
P3-084: Cerebrospinal fluid Tau and Aβ measurement and amyloid PET imaging in neurodegenerative diseases (2008) (0)
Author Correction: Asymmetric thinning of the cerebral cortex across the adult lifespan is accelerated in Alzheimer’s disease (2022) (0)
A Targeted Association Study of Blood-Brain Barrier Gene SNPs and Brain Atrophy. (2022) (0)
Centiloid harmonisation across PET cameras without using paired scan (2022) (0)
Towards a universal cortical tau sampling mask (2021) (0)
Biomarkers to unlock the Alzheimer?s disease pre-symptomatic window: Results from the AIBL Study (2013) (0)
18F-AV-133 VMAT2 Imaging in the Differential Diagnosis of Dementia With Lewy Bodies from Alzheimer's Disease (2010) (0)
WHITE MATTER HYPERINTENSITIES, AMYLOID-β, AND RISK OF COGNITIVE DECLINE IN HEALTHY OLDER PEOPLE (2019) (0)
EVIDENCE OF AMYLOID ON FLORBETABEN-PET IS ASSOCIATED WITH REDUCED EPISODIC MEMORY 10 YEARS PRIOR: RESULTS FROM THE WOMEN’S HEALTHY AGEING PROJECT (2014) (0)
Correlation between white matter hyperintensities in MRI-FLAIR and 11C-PiB PET retention: A new potential for early identification of disease (2009) (0)
IC-P3-208: In vivo characterization of 18F-BAY94-9172: A novel β-amyloid PET ligand for the diagnosis of Alzheimer's disease (2008) (0)
TAU, Aβ-AMYLOID, BRAIN STRUCTURE AND COGNITIVE FUNCTION FOLLOWING SERVICE-RELATED TRAUMATIC BRAIN INJURY IN AUSTRALIAN VIETNAM WAR VETERANS (2018) (0)
Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology (2022) (0)
No association between presence of carotid disease and 11C-PiB-PET in acute stroke patients (2011) (0)
Visual and semiquantitative validation of early and late Aβ imaging approaches using 18F-NAV4694 (2013) (0)
Using ApoE ε4 carriage as a benchmark for modelling clinically meaningful treatment effects in clinical trials of preclinical Alzheimer’s disease (2015) (0)
DIAGNOSTIC AND PROGNOSTIC POWER OF FLUID AND NEUROIMAGING MARKERS OF PATHOLOGY AND NEURODEGENERATION: THE ALZHEIMER'S IMAGING, BIOMARKERS, AND LIFESTYLE (AIBL) STUDY OF AGEING EXPERIENCE (2017) (0)
APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles (2023) (0)
Radiation dosimetry of the amyloid imaging agent 18F-BAY94-9172 in humans (2008) (0)
INCREASED PROTEIN AND FIBRE INTAKE IS ASSOCIATED WITH HIGHER PERFORMANCE IN THE AIBL PACC SCORE IN COGNITIVELY NORMAL ADULTS: AUSTRALIAN IMAGING, BIOMARKERS AND LIFESTYLE (AIBL) STUDY (2018) (0)
ALTERED PERIPHERAL MONOCYTE INNATE PHAGOCYTOSIS IN ALZHEIMER’S DISEASE (2016) (0)
IC-P2-149: In vivo assessment of β-amyloid deposition: A longitudinal study (2008) (0)
Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease. (2022) (0)
FAILURE TO SHOW A PRACTICE EFFECT ON MEMORY TESTING IS A COGNITIVE MARKER OF MCI DUE TO ALZHEIMER'S DISEASE (2016) (0)
AMYLOID IS ASSOCIATED WITH GREATER TAU BURDEN IN CLINICALLY NORMAL FEMALES RELATIVE TO MALES: FINDINGS FROM TWO INDEPENDENT COHORTS (2018) (0)
Alzheimer’s disease biomarker roadmap 2020: [18F]flortaucipir (2020) (0)
CLINICAL MEANINGFULNESS OF SHORT-TERM COGNITIVE DECLINE ON THE PRECLINICAL ALZHEIMER’S COGNITIVE COMPOSITE-5 (PACC-5) IN NORMAL OLDER ADULTS WITH ELEVATED β-AMYLOID (2019) (0)
GLOBAL TAU BURDEN CORRELATES WITH BASAL FOREBRAIN ATROPHY IN HEALTHY AGING SUBJECTS (2017) (0)
IC-P1-046: Examining the regional specificity between Aβ burden and cognition (2008) (0)
Subcortical tau‐accumulation predicts neuronal dysfunction in the cortex based on functional connectivity in 4R‐tauopathies (2022) (0)
Molecular Imaging of Neurodegeneration: The Way to New Horizons. (2022) (0)
Total plasma Aβ42/40 ratio is an early biomarker of Alzheimer’s disease progression (2015) (0)
PRECLINICAL ALZHEIMER’S DISEASE IS ASSOCIATED WITH LEARNING IMPAIRMENTS OVER SIX DAYS: RESULTS FROM THE ONLINE REPEATED COGNITIVE ASSESSMENT (ORCA) STUDY (2018) (0)
P-032 Differentiation between Alzheimer’s disease patients and healthy controls is not possible with 2-[18F]F-A-85380 pet imaging of nicotinic receptors (2007) (0)
BRAIN BETA-AMYLOID, VASCULAR FACTORS, AND COGNITION: 54-MONTH FOLLOWUP RESULTS FROM THE AIPL STUDY (2014) (0)
Clinical utility of the cogstate brief battery in Alzheimer's disease–related memory impairment (2013) (0)
VISUAL ASSESSMENT OF β-AMYLOID PET SCAN IS IMPROVED BY CAPAIBL (2018) (0)
IL-10 AND IL-12/23P40 ARE JOINTLY ASSOCIATED AS PREDICTORS OF Aβ-AMYLOID LOAD IN A BROADER BLOOD-BASED BIOMARKER PANEL (2017) (0)
Test-retest variability studies in Alzheimer's disease and normal ageing of the new amyloid imaging agent [18F]BAY 94-9172 (2009) (0)
Cerebrospinal fluid biomarker levels are not affected by aspiration or gravity drip extraction methods in Alzheimer’s disease: The AIBL study (2020) (0)
CSF P-TAU IS CORRELATED WITH TAU PET, WHILE Aβ PET CORRELATES WITH Aβ1-42 AND THE T-TAU/Aβ1-42 RATIO (2017) (0)
PLASMA BIOMARKERS OF NEOCORTICAL AMYLOID BURDEN: AN IN-DEPTH PLASMA PROFILE USING LC-MS (2016) (0)
IC-P-022 C-11 PIB PET amyloid imaging in ageing and dementia (2006) (0)
Impact of meningeal and age‐related off‐target binding on longitudinal [18F]MK6240 quantification. (2022) (0)
Cerebral microbleeds, brain beta-amyloid and clinical trajectories: results from the AIBL study of ageing (2013) (0)
Prediction of Aß and clinical outcome in patients with MCI with neuropsychological tests (2012) (0)
Cognitive change and beta-amyloid deposition in MCI subjects studied with serial 18F-Florbetaben PET over 2 years (2012) (0)
Cross‐sectional and longitudinal comparison of 18F‐MK6240 and 18F‐Flortaucipir in populations matched for centiloid, age and MMSE (2022) (0)
Novel 18F-labeled quinoline derivatives for in vivo detection of tau pathology in Alzheimer's disease (2012) (0)
INCREASED CEREBRAL BLOOD FLOW WITH INCREASED AMYLOID BURDEN IN PRECLINICAL AD (2018) (0)
KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden (2018) (0)
BRAIN BETA-AMYLOID, VASCULAR FACTORS, AND COGNITION: 54-MONTH FOLLOWUP RESULTS FROM THE AIPL STUDY (2014) (0)
UTILITY OF THE COGNIGRAM BRIEF BATTERY IN ASSESSING COGNITIVE CHANGES ASSOCIATED WITH AB AND APOE GENOTYPE IN PRECLINICAL ALZHEIMER'S DISEASE (2014) (0)
The management impact of [18F]AV-133 VMAT2 PET in atypical Parkinson’s disease (2014) (0)
P2.097 A reactive nitrogen species scavenger is neuroprotective in multiple Parkinson's disease animal models (2009) (0)
QUANTITATIVE SUSCEPTIBILITY MAPPING OF THE HIPPOCAMPUS PREDICTS HIPPOCAMPAL ATROPHY IN A b + ELDERLY CONTROLS AND ALZHEIMER’S DISEASE PATIENTS (2017) (0)
P-066 Characterization of PIB binding to white matter (2007) (0)
Detectable levels of white matter PHF-tau in Alzheimer's disease (2013) (0)
NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN (2014) (0)
The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target Regions (2022) (0)
45. Gender differences in aging effect on the 5-HTlA receptor with [11C-carbonyl]way100635 PET (2000) (0)
REGIONAL ASSOCIATION BETWEEN CORTICAL VOLUMES AND IMAGING TAU PATHOLOGY USING 18F-AV1451 AND 18F-THK5351 (2016) (0)
Correlation between Amyloid Burden and Memory Impairment: A C-PIB PET Cross Sectional Study (2008) (0)
IC-P-012 C-11 PIB and F-18 FDG in the diagnosis of Alzheimer’s disease (2006) (0)
A retinal hyperspectral imaging biomarker for Alzheimer’s disease: Preliminary study of the influence of eye diseases on imaging scores (2020) (0)
MR-less cortical surface-projection of PET images from 11C- and 18F-labeled radiotracers (2013) (0)
Genetic risk for attention‐deficit/hyperactivity disorder is associated with amyloid‐dependent cognitive decline in older adults (2022) (0)
LONGITUDINAL RATES OF ATROPHY IN FAMILIAL ALZHEIMER'S DISEASE (2014) (0)
EFFECTS OF MAPT OVER BRAIN GREY MATTER ATROPHY IN THE AIBL COHORT (2016) (0)
PLASMA BIOMARKER WITH HIGH ACCURACY IN PREDICTING BRAIN AMYLOID-β BURDEN: INITIAL RESULTS ACROSS TWO INDEPENDENT LARGE COHORTS—NCGG (JAPAN) AND AIBL (AUSTRALIA) (2018) (0)
Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials. (2023) (0)
The Australian Biomarker, Imaging and Lifestyle Study: Phase I amyloid imaging results (2009) (0)
Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals (2022) (0)
Examining the structural correlates of amyloid‐beta in people with DLB (2021) (0)
The trinity of tau, trauma, and time (2019) (0)
A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort (2017) (0)
Progress of the australian imaging, biomarkers, and lifestyle (AIBL) cohort with 72 months of assessment: Attrition, disease progression, and mortality (2015) (0)
O2-13-04 WHITE MATTER HYPERINTENSITIES AND CSF BIOMARKERS IN RELATION TO CLINICAL SYMPTOM ONSET IN PRECLINICAL ALZHEIMER’S DISEASE (2018) (0)
Identification of genetic markers linked to accelerated brain volume changes in Aβ‐positive population (2020) (0)
Head‐to‐Head comparison between Philips Gemini TF64 and Siemens Biograph Vision 600 for brain amyloid Centiloid quantitation (2022) (0)
Amyloid angiopathy may contribute to white‐matter hyperintensities in Alzheimer’s disease (2020) (0)
Evaluation of the novel F-18-labeled PET tracer SMBT-1 for imaging astrogliosis in Alzheimer's disease (2020) (0)
18F-AV-133 VMAT2 imaging in the differential diagnosis of dementia with Lewy Bodies from Alzheimer's disease (2010) (0)
VERBAL LEARNING AND BETA-AMYLOID: REPEATED ADMINISTRATION OF THE INTERNATIONAL SHOPPING LIST TEST (2018) (0)
PET IMAGING OF BRAIN MUSCARINIC M1 RECEPTORS WITH F-18-FLUROBENZYL DEXETIMIDE: FIRST IN HUMAN STUDIES (2019) (0)
Higher coffee consumption is associated with slower cognitive decline and Aβ‐amyloid accumulation over 126 months: Data from the AIBL study (2021) (0)
Self-reported confusion is related to global and regional β-amyloid: data from the Women’s healthy ageing project (2017) (0)
NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN (2014) (0)
AMYLOID-POSITIVE VERSUS NEGATIVE AMCI: SIMILARITIES AND DIFFERENCES IN NEUROPSYCHOLOGY AND NEUROIMAGING PROFILES (2016) (0)
BDNF, Aβ, and cortical atrophy in preclinical Alzheimer's disease (2015) (0)
Aβ-related memory decline in preclinical Alzheimer's disease is delayed in ApoE-ɛ4 non-carriers (2015) (0)
O2-06-05 CORRELATION OFAMYLOID PET EXPRESSED IN CENTILOID UNITS WITH NEUROPATHOLOGICAL FINDINGS IN ALZHEIMER’S DISEASE (2018) (0)
REFINING THE NATURAL HISTORY OF GLOBAL AND REGIONAL Aβ-AMYLOID DEPOSITION IN SPORADIC ALZHEIMER’S DISEASE (2017) (0)
AGE INCREASES RATE OF AB- AND E4-RELATED MEMORY DECLINE IN PRECLINICAL ALZHEIMER’S DISEASE (2016) (0)
MIDLIFE VASCULAR RISK, APOLIPOPROTEIN E-E4, AND AMYLOID STATUS 20 YEARS LATER: RESULTS FROM THE WOMEN’S HEALTHY AGEING PROJECT (2014) (0)
Amyloid imaging: what can it tell us? (2016) (0)
Plasma glial fibrillary acidic protein is associated with reactive astrogliosis assessed via 18F‐SMBT‐1 PET (2022) (0)
Cross-sectional cerebral volumetric differences and associations with estimated time to age-at-onset in familial Alzheimer's disease: Findings from the DIAN study (2012) (0)
O1-04-02 Initial results from human studies of a novel F-18 PET ligand for brain beta-amyloid imaging (2007) (0)
TAU, Aß AND COGNITION IN HEALTHY ELDERLY: PRELIMINARY DATA FROM THE AIBL COHORT (2016) (0)
PiB as antecedent biomarker of Alzheimer's disease (2009) (0)
Relationship between longitudinal changes in amyloid deposition and incident dementia in non‐demented individuals age 80+ (2022) (0)
IC-P-084 Nicotinic receptor upregulation and the cognitive effects of galantamine in Alzheimer’s disease: A human in vivo study using [18F]F-A-85380 PET (2006) (0)
The Lancet Neurology Amyloid and FDG-PET in the diagnostic work-up of Alzheimer’s disease and other dementias (2020) (0)
A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer’s Disease (2016) (0)
Correlation of PiB-PET to post-mortem A{beta} plaque load (2010) (0)
Combining white matter density and atrophy information to improve the characterization of axonal loss in Alzheimer's disease (2013) (0)
PARTIAL VOLUME CORRECTION USING EITHER PMOD ® OR CAPAIBL ® DOES LITTLE TO IMPROVE 18F-AV1451 PET QUANTIFICATION (2018) (0)
P-092 Nicotinic receptors are not responsible for improved cognitive performance by galantamine in early Alzheimer’s disease: A 2-[18F]f-a-85380 PET study (2007) (0)
EXAMINING THE RESILIENCE OF SUPERAGERS: RISK OF CLINICAL PROGRESSION AND Aβ-ASSOCIATED MEMORY DECLINE OVER 8 YEARS (2018) (0)
Cognitive & Behavioral Assessment Sensitivity of composite scores to amyloid burden in preclinical Alzheimer'sdisease:IntroducingtheZ-scoresofAttention,Verbalfluency, and Episodic memory for Nondemented older adults composite score (2016) (0)
PLASMA CORTISOL, AMYLOID-B, AND COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER’S DISEASE (2016) (0)
P1-384 Association of AD neuropathological hallmarks with biological metals (2006) (0)
In an amnestic MCI population, those with high PIB binding perform more poorly on memory tests than those with low binding (2010) (0)
The Australian Imaging, Biomarkers and Lifestyle-Rate of Change sub-study (AIBL-ROCS): Rationale, design, acceptability and pilot data for the first three months of assessment (2012) (0)
Effect of Aβ burden and apolipoprotein E-ε4 on cognitive decline at 18 months in healthy older adults (2012) (0)
Beta-amyloid imaging with 18F-BAY94-9172 (AV1/ZK) PET in the differential diagnosis of Alzheimer's disease from fronto-temporal lobar degeneration (2008) (0)
Objectively measured physical activity and cognition in cognitively normal older adults: A longitudinal analysis of the Australian Imaging Biomarkers and Lifestyle (AIBL) study (2022) (0)
Longitudinal modeling of joint PIB/MRI changes in Alzheimer's disease (2012) (0)
AMYLOID PET IS MORE THAN JUST POSITIVE OR NEGATIVE: AMYLOID LEVEL IMPACTS RISK OF CLINICAL PROGRESSION IN NORMAL INDIVIDUALS (2019) (0)
35. Cocaine-related cues elicit craving and activate cortical circuits relevant to episodic memory (1996) (0)
Identification of neurodevelopmental gene variants implicated in age‐related brain morphological changes and cortical atrophy (2021) (0)
Sigmoidal kinetics of BETA-AMYLOID deposition: Twenty-year interval between normality and fully developed Alzheimer's disease (2012) (0)
Subcortical tau‐accumulation predicts neuronal dysfunction in the cortex based on functional connectivity in 4R‐tauopathies (2022) (0)
Semi‐quantitative [11C]PiB and [15O]H2O PET measures of cerebrospinal fluid dynamics discriminate amyloid load but not cognitive status (2021) (0)
Suboptimal sleep efficiency and duration predicts rate of accumulation of Aβ‐ Amyloid in cognitively normal older adults (2022) (0)
PRECLINICAL EFFECTS OF Aβ DEPOSITION ON EPISODIC MEMORY AND DISEASE PROGRESSION (2014) (0)
Improved Imaging-Based Diagnosis of PSP by [F-18]PI-2620 Tau PET (2020) (0)
Cerebral microbleeds in dementia with Lewy bodies. (2022) (0)
GLOBAL TAU BURDEN CORRELATES WITH BASAL FOREBRAIN ATROPHY IN HEALTHY AGING SUBJECTS (2017) (0)
THK523 selectively binds to neurofibrillary tangles and neuropils in people with Alzheimer's disease (2013) (0)
101. Brain Amyloid Imaging with 11C-PIB PET (2009) (0)
DIFFERENTIAL RISK FACTORS FOR PROGRESSION TO MCI/DEMENTIA BY AMYLOID-BETA STATUS (2018) (0)
Longitudinal evaluation of basal forebrain atrophy and its association to beta-amyloid burden and hippocampal volume in Alzheimer's disease (2013) (0)
O4-02-05 Total exchangeable Cu2+ protein binding sites are elevated in Alzheimer’s disease (2006) (0)
When is Progressive Aphasia Due to Alzheimer's Disease? A PIB-PET Study (2010) (0)
One year tau progression measured with F‐18 MK6240 PET (2020) (0)
PARTIAL VOLUME CORRECTION USING EITHER PMOD (cid:1) OR CAPAIBL (cid:1) DOES (2018) (0)
RECEIVER OPERATING CHARACTERISTICS (ROC) OF FLOW AND AMYLOID LOAD INDICES FROM BRAIN MAPS OF [11C]PIB RETENTION IN ALZHEIMER'S DISEASE (2014) (0)
C-11 PIB PET imaging in atypical presentation of Alzheimer's disease (2006) (0)
313: Imaging brain amyloid in ageing and dementia with C-11 PIB PET (2007) (0)
Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology (2022) (0)
ASSESSING THE ACCURACY OF A CT-BASED APPROACH TO THE PARTIAL VOLUME CORRECTION OF FLUTEMETAMOL-PET IMAGES (2014) (0)
Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia (2016) (0)
TAU IMAGING WITH 18F-MK6240 IN ALZHEIMER’S DISEASE AND OTHER DEMENTIAS (2019) (0)
IC‐P‐172: Withdrawn (2015) (0)
How lifestyle shapes the brain: Associations between physical activity, sleep, beta‐amyloid and cognitive function in older adults (2021) (0)
Between SNAP and a hard Aβ rock: Characterizing the fate of preclinical Alzheimer's disease (2015) (0)
Characteristics of the neighborhood built environment are associated with MRI brain volumetric and amyloid beta burden measures: Findings from the australian imaging, biomarkers, and lifestyle (AIBL) study (2015) (0)
O1-02-07: In vivo characterization of 18F-BAY94-9172: A novel β-amyloid PET ligand for the diagnosis of Alzheimer's disease (2008) (0)
RECENT FINDINGS OF NOVEL BLOOD COMPONENTS’ AMYLOID-BETA MEASURES (2019) (0)
Healthy subjects with abnormal levels of amyloid‐B and tau have lower cortical volumes in the mesial temporal region (2020) (0)
Modulation of beta-amyloid-related cognitive decline by brain-derived neurotrophic factor Val66Met polymorphism in preclinical Alzheimer's disease (2013) (0)
Longitudinal modeling of joint PiB/MRI changes in Alzheimer's disease (2012) (0)
Cerebral microhaemorrhage and brain A{beta} in healthy ageing and Alzheimer's disease (2011) (0)
Empirically derived composite cognitive test scores to predict preclinical and clinical stages of Alzheimer’s disease (2021) (0)
LONGITUDINAL ASSESSMENT OF Aβ ACCUMULATION WITH FLUTEMETAMOL (2017) (0)
D 2 dopamine receptors in pituitary tumors (1987) (0)
Progressive white matter abnormalities in autosomal-dominant Alzheimer's disease: Results of the DIAN study (2012) (0)
Differential diagnosis of dementia with Lewy bodies from Alzheimer's disease using [18F]-AV-133, a novel PET tracer for VMAT2 (2010) (0)
BDNF, Aβ, and cortical atrophy in preclinical Alzheimer's disease (2015) (0)
Postmortem neocortical 3 H‐PiB binding and levels of unmodified and pyroglutamate Aβ in Down syndrome and sporadic Alzheimer’s disease (2022) (0)
PiB PET Classification: A model to determine those who are at risk of developing AD (2009) (0)
EVIDENCE OF AMYLOID ON FLORBETABEN-PET IS ASSOCIATED WITH REDUCED EPISODIC MEMORY 10 YEARS PRIOR: RESULTS FROM THE WOMEN’S HEALTHY AGEING PROJECT (2014) (0)
The consequences of Aβ deposition in aging and Alzheimer's disease: Results from 366 elderly subjects (2011) (0)
REGIONAL ASSOCIATION BETWEEN CORTICAL VOLUMES AND IMAGING TAU PATHOLOGY USING 18F-AV1451 AND 18F-THK5351 (2016) (0)
Implementation of the centiloid transformation for F-18 nav4694: Comparison with PiB (2015) (0)
Combining two large clinical cohorts (AIBL and ADNI) to identify multiple lipid metabolic pathways in prevalent and incident Alzheimer's disease. (2020) (0)
Amyloid imaging in Alzheimer’s disease and dementia with lewy bodies with 11C-PIB-PET (2005) (0)
THE LEWY STUDY: AN AUSTRALIAN LONGITUDINAL COHORT STUDY OF DEMENTIA WITH LEWY BODIES (2019) (0)
Effects of partial volume correction on the analysis of 11C-PiB PET in assessing Alzheimer's disease (2010) (0)
ANTIHYPERTENSIVE TREATMENT AND LONGITUDINAL Aβ MEASURES: RESULTS FROM THE AIBL STUDY OF AGEING (2016) (0)
P2-291 C-11 PIB and F-18 FDG in the diagnosis of Alzheimer’s disease (2006) (0)
BETA-AMYLOID SPECIFIC GENOMIC NETWORKS DEFINE CIS AND TRANS RELATIONSHIPS IN PARTICIPANTS WITH ALZHEIMER’S DISEASE (2018) (0)
Characterizing patterns of atrophy between cognitively unimpaired healthy elderly controls with either Alzheimer's disease or suspected non-alzheimer's disease pathophysiology (2015) (0)
Subjective memory complainers in the AIBL cohort: Hypervigilance amongst the worried well, or individuals at increased risk of Alzheimer's disease? (2010) (0)
P3-171: Redefining “normal” cognitive performance in ageing using Aβ neuroimaging (2008) (0)
Midlife vascular risk and late-life amyloid burden: Data from the Women's Healthy Ageing Project (WHAP) (2013) (0)
DIFFERENCE IN THE RATE OF COGNITIVE CHANGE BETWEEN INDIVIDUALS WITH AND WITHOUT VASCULAR RISK FACTORS: A LONGITUDINAL STUDY (2016) (0)
Apparent fibre density: A novel MRI approach that identifies specific white matter tracts affected in Alzheimer's disease and MCI (2012) (0)
AMYLOID PET IS MORE THAN JUST POSITIVE OR NEGATIVE: AMYLOID LEVEL IMPACTS RISK OF CLINICAL PROGRESSION IN NORMAL INDIVIDUALS (2019) (0)
Subjective cognitive decline and Aβ status are associated with longitudinal episodic memory decline in cognitively normal older adults (2015) (0)
β-AMYLOID AND TAU IMAGING IN OBSTRUCTIVE SLEEP APNOEA: AUSTRALIAN IMAGING BIOMARKERS AND LIFESTYLE-VETERANS STUDY (AIBL-VETS) (2017) (0)
VASCULAR RISK MEASURES AND LONGITUDINAL Aβ ACCUMULATION: RESULTS FROM THE AIBL STUDY OF AGEING (2017) (0)
Aβ RELATED MEMORY DECLINE AND HIPPOCAMPAL VOLUME LOSS IN MILD COGNITIVE IMPAIRMENT (2016) (0)
A management impact study of VMAT2 PET with [18F]AV-133 in patients with uncertain parkinsonian features: Preliminary findings (2013) (0)
The effect of vascular risk factors on the rate of cognitive change in older adults: Data from the Australian Imaging Biomarkers and Lifestyle (AIBL) flagship study (2013) (0)
Mesial temporal tau in amyloid-β-negative cognitively normal older persons (2022) (0)
P1-306: In vivo assessment of β-amyloid deposition: A longitudinal study (2008) (0)
SPON1 Is Associated with Amyloid-β and APOE ε4-Related Cognitive Decline in Cognitively Normal Adults (2019) (0)
Automatic 11C PiB SUVR quantification (2013) (0)
FIXEL-BASED ANALYSIS OF FIBRE TRACT DEGENERATION IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE (2017) (0)
S.26.03 Potential role of amyloid imaging in mild cognitive impairment in Parkinson's disease (2014) (0)
Associations between gonadotropins, testosterone, plasma Aβ and PiB retention in men with subjective memory complaints or mild cognitive impairment (2010) (0)
Emission Imaging in Dementia (2012) (0)
Preclinical effects of A{beta} deposition on episodic memory and disease progression (2014) (0)
Level of physical activity is associated with hippocampal volume in a subgroup of the AIBL cohort (2012) (0)
An update on an AIBL blood-based biomarker panel for the prediction of Aβ burden (2012) (0)
Characterizing patterns of atrophy between cognitively unimpaired healthy elderly controls with either Alzheimer's disease or suspected non-Alzheimer's disease pathophysiology (2015) (0)
18F-AV1451 TAU QUANTIFICATION WITHOUT MRI (2017) (0)
P1-238: The Australian biomarker, imaging and lifestyle study: Preliminary PiB results (2008) (0)
SENSITIVITY OF AN ALZHEIMER’S DISEASE COOPERATIVE STUDY: PRECLINICAL ALZHEIMER’S COGNITIVE COMPOSITE (PACC) BASED ON COMPUTERIZED TESTS TO AMYLOID LOAD IN PRECLINICAL AD (2017) (0)
A two-year longitudinal assessment of A{beta} deposition in MCI with 18F-Florbetaben (2012) (0)
Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer’s disease (2023) (0)
Recent advances in tau imaging (2014) (0)
CEREBROVASCULAR DISEASE, ALZHEIMER’S DISEASE BIOMARKERS AND LONGITUDINAL COGNITIVE DECLINE (2016) (0)
Elevated PiB precedes dementia in autosomal-dominant Alzheimer's disease: PiB, FDG and atrophy in the DIAN cohort (2012) (0)
P2-009: Characterisation of [18]-BF227 binding to α-synuclein (2008) (0)
EXOSOMAL MIRNA AS BIOMARKERS FOR DIAGNOSING ALZHEIMER'S DISEASE (2014) (0)
IC-03-03: The Australian Biomarker, Imaging and Lifestyle Study: Preliminary PIB results (2008) (0)
PIB-PET CENTILOID QUANTIFICATION USING CAPAIBL (2016) (0)
Cortical surface projection of PET images from 11C- and 18F-labeled radiotracers without magnetic resonance imaging (2013) (0)
P3-462 CONSIDERATION OF PRECLINICAL AD FROM THE PERSPECTIVE OF NORMAL AGING: AMYLOID-b RELATED CHANGES IN FLUID AND CRYSTALLIZED INTELLIGENCE IN A ROBUST SAMPLEOF HEALTHY OLDER ADULTS (2017) (0)
Blood Borne Aβ Dimer Correlates With Clinical Markers of Alzheimer's Disease (2009) (0)
The AIBL study: Baseline data from a multicenter, prospective longitudinal study of ageing in 1,100 volunteers (2009) (0)
Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology. (2023) (0)
In vivo detection of tau protein deposits in Alzheimer's disease using 18F-labeled 2-phenylquinoline derivatives (2013) (0)
Relation between rates of Aβ deposition, APOE genotype and cognition: Results from a 3- to 5-year longitudinal study (2012) (0)
Amyloid-β and its relevance to the detection of Alzheimer's disease in blood plasma: Findings from the first phase of the Australian Imaging, Biomarker and Lifestyle (AIBL) flagship study of ageing (2009) (0)
Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease (2022) (0)
Plasma Aβ biomarker associated with cognitive decline in preclinical Alzheimer’s disease (2020) (0)
In vitro characterization of [F-18]-florbetaben, an A beta imaging radiotracer (2012) (0)
PIB PET CENTILOID QUANTIFICATION USING CAPAIBL (2016) (0)
Web-based automated PET and MR quantification (2015) (0)
AUTOMATED REPORTING OF AMYLOID PET QUANTIFICATION ON BRAIN SURFACE THROUGH A WEB INTERFACE (2014) (0)
MIDLIFE VASCULAR RISK, APOLIPOPROTEIN E-E4, AND AMYLOID STATUS 20 YEARS LATER: RESULTS FROM THE WOMEN’S HEALTHY AGEING PROJECT (2014) (0)
Comparing Pathological Risk Factors for Dementia between Cognitively Normal Japanese and Americans (2021) (0)
Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies (2014) (0)
CLINICAL MEANINGFULNESS OF SHORT-TERM COGNITIVE DECLINE ON THE PRECLINICAL ALZHEIMER’S COGNITIVE COMPOSITE-5 (PACC-5) IN NORMAL OLDER ADULTS WITH ELEVATED β-AMYLOID (2019) (0)
A MASS SPECTROMETRY-BASED DISCOVERY AND REPLICATION OF A MULTI-ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY (2017) (0)
Lipidomic signatures for APOE genotypes provides new insights about mechanisms of resilience in Alzheimer’s disease (2021) (0)
THE IMPACT OF APOE ε4 CARRIAGE ON Aβ-AMYLOID DEPOSITION IN AIBL (2017) (0)
Identification of Pre-Clinical Alzheimer's Disease in a Population of Elderly Cognitively Normal Participants. (2019) (0)
Combining white matter density and atrophy information to improve the characterization of axonal loss in Alzheimer's disease (2013) (0)
Discordant low amyloid‐β PET and high neocortical tau PET retention (2021) (0)
The amyloid-β pathway in Alzheimer's disease: a plain language summary. (2023) (0)
Investigating a new neocortical mask for Centiloid quantification (2022) (0)
A voxel-based morphometry study of volumetric MRI in familial Alzheimer's disease (2012) (0)
TAU IMAGING IN ALZHEIMER’S DISEASE WITH [F-18]-MK6240, A SECOND GENERATION SELECTIVE TAU TRACER (2018) (0)
COMPARISON OF THE NATURAL HISTORY OF NEOCORTICAL Aβ-AMYLOID, HIPPOCAMPAL VOLUME AND PACC IN SPORADIC AD (2018) (0)
Differential Diagnosis of Dementia with FDG-PET and Voxel-Based Statistical Analysis: Impact of Alternative Normal Databases (2010) (0)
18F-AV1451 TAU QUANTIFICATION WITHOUT MRI (2017) (0)
Gender differences in the relationship between Aβ burden and memory (2010) (0)
O 104-06 CORRELATION OF MEMORY DYSFUNCTION AND AMYLOID BURDEN IN MILD COGNITIVE IMPAIRMENT (2007) (0)
TAU, Aβ-AMYLOID, BRAIN STRUCTURE AND COGNITIVE FUNCTION FOLLOWING SERVICE-RELATED TRAUMATIC BRAIN INJURY IN AUSTRALIAN VIETNAM WAR VETERANS (2018) (0)
AMNESTIC MILD COGNITIVE IMPAIRMENT ADULTS IN EVENT- RELATED POTENTIALS DURING MEMORY ENCODING IN AVISUOSPATIAL WORKING MEMORY TASK (2017) (0)
COMPARISON OF EARLY DYNAMIC AMYLOID AND TAU-PET SCANS TO 18F-FDG-PET IMAGE (2016) (0)
The consequences of Aβ deposition in aging and Alzheimer's disease: results from 366 elderly subjects (2011) (0)
Tau imaging with 18F-MK6240 in Alzheimer’s disease and Traumatic Brain Injury (2019) (0)
EFFECTS OF AB AND BDNF VAL66MET ON EPISODIC MEMORY, HIPPOCAMPAL VOLUME AND SERUM BDNF IN PRECLINICAL ALZHEIMER’S DISEASE (2016) (0)
Comparison of PiB and FDG in the differential diagnosis of Alzheimer's disease (2008) (0)
Cross-sectional cerebral volumetric differences and associations with estimated time to age-at-onset in familial Alzheimer's disease: Findings from the DIAN study (2012) (0)
Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimerâ€TMs disease (2019) (0)
Basal forebrain atrophy and tau pathology are correlated in prodromal AD (2020) (0)
Molecular imaging in dementia: journey to the end of the night (2009) (0)
TAU, Aβ-AMYLOID, AND COGNITIVE FUNCTION FOLLOWING SERVICE-RELATED TRAUMATIC BRAIN INJURY IN VIETNAM WAR VETERANS (2017) (0)
The Neuroinflammatory Response in Plaqes and Amyloid Angiopathy in Alzheimer's Disease: Therapeutical Implications (2007) (0)
AUTOMATED REPORTING OF AMYLOID PET QUANTIFICATION ON BRAIN SURFACE THROUGH A WEB INTERFACE (2014) (0)
PARTIAL VOLUME CORRECTION USING EITHER PMOD® OR CAPAIBL® DOES LITTLE TO IMPROVE 18F-AV1451 PET QUANTIFICATION (2018) (0)
GENETIC VARIATION WITHIN GENES OF THE SPHINGOLIPID METABOLISM PATHWAY AND THEIR ASSOCIATION WITH ALZHEIMER'S DISEASE RISK AND RELATED PHENOTYPES (2014) (0)
APOE GENOTYPE-DEPENDENT EFFECTS OF DIET AND PHYSICAL ACTIVITY ON COGNITION AND ALZHEIMER'S-RELATED PATHOLOGY: DATA FROM THE AIPL STUDY OF AGEING (2014) (0)
MK-6240-PET NEUROFIBRILLARY TANGLE PATTERN SUBTYPES ARE ASSOCIATED WITH DISTINCT MEMORY AND COGNITIVE PERFORMANCE (2019) (0)
P2-371 Nicotinic receptor upregulation and the cognitive effects of galantamine in Alzheimer’s disease: A human in vivo study using [18F]F-A-85380 PET (2006) (0)
THE CAPTAINS STUDY: STANDARDIZING VISUAL INTERPRETATION STRATEGIES FOR AMYLOID PET TRACERS (2019) (0)
ASSESSING GLOBAL AND REGIONAL Aβ-AMYLOID DEPOSITION IN THE BRAIN WITH MULTIPLE Aβ-TRACERS USING THE CENTILOID SCALE (2019) (0)
Techniques for assessing Alzheimer's disease progression (2015) (0)
PiB PET Classification: A model to determine those who are at risk of developing Alzheimer's disease (2009) (0)
Implementation and validation of a method for automated quantification of [18F]flutemetamol imaging data (2012) (0)
Exploring CSF biomarkers that add value to CSF AB42, t-Tau and p-Tau for correlation with β-amyloid PET status (2020) (0)
Quantitative thresholds for 18F‐florbetaben PET for the detection of low amyloid load (2020) (0)
Brain and hippocampal rates of atrophy in familial Alzheimer's disease mutation carriers: Preliminary findings from the DIAN study (2012) (0)
Greater rate of atrophy in elderly with high versus low Aβ deposition (2011) (0)
Interaction between 18F-THK5317, 18F-flutemetamol SUVR and cortical thickness (2015) (0)
HIGHER Aβ BURDEN IN HEALTHY APOE-E4 CARRIERS IS ASSOCIATED WITH SUBJECTIVE MEMORY COMPLAINTS: RESULTS FROM THE FLUTEMETAMOL AND PIB AIPL COHORTS (2014) (0)
Identification of concordant plasma lipid signatures in Alzheimer’s disease: Validation between two independent studies of Alzheimer’s disease (2020) (0)
[11C]WIN-35,428 PET Imaging Reveals Decreased Dopamine Transporter Density in Abstinent Methamphetamine Users (1998) (0)
PET imaging of amyloid burden and cognitive assessment for the reliable discrimination between healthy aging, subjective memory impairment and mild cognitive impairment (2012) (0)
Brain and hippocampal rates of atrophy in familial Alzheimer's disease mutation carriers: Preliminary findings from the DIAN study (2012) (0)
Using imputation to harmonize longitudinal measures of cognition across two large cohorts: AIBL and ADNI (2020) (0)
Comparing the longitudinal progression of CSF biomarkers with PET Amyloid biomarkers for Alzheimer’s disease (2022) (0)
316 - Lewy Body Study: An Australian longitudinal biomarker study of dementia with Lewy bodies (2020) (0)
Preclinical and clinical imaging techniques as pathophysiological biomarkers — A preface to the special issue “Brain Imaging” (2022) (0)
Investigating the impact of scatter correction on Centiloid (2021) (0)
The association between mesial temporal tau with age, cognition and neocortical tau in Aβ cognitively unimpaired individuals using MK‐6240 (2020) (0)
Unpacking cognitive composites: A longitudinal analysis (2021) (0)
PARTICIPANTS WITH A POSITIVE AMYLOID SCAN IN THE WOMEN’S HEALTHY AGEING PROJECT HAD SIGNIFICANTLY WORSE EPISODIC MEMORY THAN THOSE WITH A NEGATIVE SCAN (2014) (0)
Cognitive assessments as estimators of neocortical beta-amyloid burden in the AIBL cohort (2012) (0)
MK-6240-PET NEUROFIBRILLARY TANGLE PATTERN SUBTYPES ARE ASSOCIATED WITH DISTINCT MEMORY AND COGNITIVE PERFORMANCE (2019) (0)
Plasma p217+tau concordance with 18F‐NAV4694 beta‐amyloid and 18F‐MK6240 tau PET in mild Alzheimer’s disease and cognitively unimpaired participants in the AIBL/ADNeT cohort (2021) (0)
P2-021: Profiling beta-amyloid in the Alzheimer's disease brain (2012) (0)
P2-271 OPTIMAL REFERENCE REGION TO MEASURE LONGITUDINAL AMYLOID-BETACHANGEWITH 18F-FLORBETABEN PET (2019) (0)
18F-florbetaben Aβ imaging in mild cognitive impairment (2013) (0)
Centiloid harmonisation strategies across longitudinal studies: Evaluation on AIBL, ADNI and OASIS3 (2021) (0)
P2-054: Pattern of Aβ deposition in familial Alzheimer's disease is not related to mutation type or cognitive status (2008) (0)
SELF-REPORTED PHYSICAL ACTIVITY IS ASSOCIATED WITH TAU BURDEN AS MEASURED BY PET (2017) (0)
Automatic 11C PiB SUVR quantification (2013) (0)
The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis. (2022) (0)
Analysis of Peripheral Blood Biomarkers: Towards the Early Diagnosis Alzheimer's Disease (2010) (0)
Altered levels of plasma kallikrein‐7 in prodromal Alzheimer’s disease (2022) (0)
Impact of meningeal and age‐related off‐target binding on longitudinal [18F]MK6240 quantification (2022) (0)
EANM Springer Prizes awarded at EANM’15 Hamburg (2015) (0)
PAIRED ASSOCIATE LEARNING DEFICITS ASSOCIATED WITH ELEVATED BETA-AMYLOID IN COGNITIVELY NORMAL OLDER ADULTS (2018) (0)
Divergent complex network patterns of amyloid-b deposition between language and typical alzheimer's presentations (2015) (0)
COMORBIDITY OF CEREBROVASCULAR DISEASE AND AMYLOID-β AND ITS INFLUENCE ON RATES OF COGNITIVE DECLINE AND NEURODEGENERATION (2018) (0)
The effects of mesial temporal tau in Ab‐negative cognitively normal older adults (2020) (0)
Baseline and follow-up neuroimaging results from the Australian imaging, biomarker, and lifestyle flagship study of aging (AIBL) (2010) (0)
Alzheimer’s disease specific MRI brain regions are differentially associated with accelerated decline as defined using sigmoidal cognitive turning point methodology in amyloid‐positive AIBL participants (2022) (0)
Potential use of cogstate battery to monitor adverse events in individuals taking part in clinical trials of anti-amyloid drugs (2015) (0)
Cross-Sectional and Longitudinal Comparison of Tau Imaging with 18F-MK6240 and 18F-Flortaucipir in Populations Matched for Age, MMSE and Brain Beta-Amyloid Burden (2023) (0)
Incidence and associations of lobar microbleeds: Results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) (2012) (0)
Episodic memory decline is associated with cortical amyloid accumulation in healthy community-dwelling, non demented older adults (2011) (0)
P1-277: Examining the regional specificity between Aβ burden and cognition (2008) (0)
Automatic image analysis of AV133 PET images (2012) (0)
CORRECTING FOR PET SCANNER CHANGES IN LONGITUDINAL STUDIES (2019) (0)
Profiling beta-amyloid in the Alzheimer's disease brain (2012) (0)
LONGITUDINAL EVALUATION OF THE NATURAL HISTORY OF Aβ IN PLASMA AND BRAIN (2019) (0)
Greater rate of atrophy in elderly with high versus low Aβ deposition (2011) (0)
P3-620: Increased protein and fibre intake is associated with higher performance in the ABIL PACC score in cognitively normal adults: Australian imaging, biomarkers and lifestyle (ABIL) study (2006) (0)
Quantitative thresholds for 18 F‐florbetaben PET for the detection of low amyloid load: Neuroimaging / Optimal neuroimaging measures for early detection (2020) (0)
TAU AND Aβ-AMYLOID IMAGING IN NIEMANN-PICK TYPE C (2017) (0)
Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods (2021) (0)
PET tau imaging in Alzheimer's disease using novel 18F-labeled 2-phenylquinoline derivatives (2013) (0)
Rates of hippocampal atrophy are associated with increased PiB-PET amyloid load in elderly controls (2012) (0)
Early-Phase F-18-PI-2620 Tau-PET Imaging as a Surrogate Marker of Neurodegeneration (2019) (0)
TAU, Aβ-AMYLOID, AND COGNITIVE FUNCTION FOLLOWING SERVICE-RELATED TRAUMATIC BRAIN INJURY IN VIETNAM WAR VETERANS (2017) (0)
Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods (2021) (0)
18 F‐PI‐2620 tau‐PET in corticobasal syndrome (ActiGliA cohort): Neuroimaging: Other neurodegenerative disorders (2020) (0)
Longitudinal evaluation of basal forebrain atrophy and its association with beta-amyloid burden and hippocampal volume in Alzheimer's disease (2013) (0)
Amyloid-beta remains a membrane peptide after cleavage. implications for secretion and kinetics of abeta turnover in human brain (2015) (0)
A Machine Learning Approach for Computer-Aided Detection of Cerebral Microbleed Using High-order Shape Features (2014) (0)
Beta-amyloid and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease (2013) (0)
Investigating Alzheimer's disease in the blood cellular fraction (2011) (0)
JAMA Paper supplement (2015) (0)
Rates of hippocampal atrophy are associated with increased PiB-PET amyloid load in elderly controls (2012) (0)
P3-469 FREE AND CUED SELECTIVE REMINDING TEST PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE IN PEOPLE WITH MILD COGNITIVE IMPAIRMENT (2018) (0)
In vivo imaging of brain proteinopathies (2018) (0)
1．[Invited keynote lecture] The Tao of Tau: implications for in vivo tau imaging (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Victor L. L. Villemagne?

Victor L. L. Villemagne is affiliated with the following schools:

Edith Cowan University
University of Melbourne
University of Pittsburgh
Monash University

Victor L. L. Villemagne's Academic­Influence.com Rankings

Victor L. L. Villemagne's Degrees

Why Is Victor L. L. Villemagne Influential?

Victor L. L. Villemagne's Published Works

Published Works

What Schools Are Affiliated With Victor L. L. Villemagne?

Victor L. L. Villemagne's AcademicInfluence.com Rankings